Goldman Sachs’s Teva Pharmaceuticals TEVA Stock Holding History

Goldman Sachs’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,389,900	Closed	-$106M	–	6969
2025 Q4	$106M	Buy	3,389,900 +17,700	+0.5%	+$436K	0.01%	968
2025 Q3	$68.1M	Buy	3,372,200 +732,300	+28%	+$12.9M	0.01%	1198
2025 Q2	$44.2M	Sell	2,639,900 -3,631,500	-58%	-$58.6M	0.01%	1423
2025 Q1	$96.4M	Buy	6,271,400 +3,744,800	+148%	+$66.9M	0.02%	804
2024 Q4	$55.7M	Sell	2,526,600 -748,600	-23%	-$13.6M	0.01%	1200
2024 Q3	$59M	Sell	3,275,200 -200,000	-6%	-$3.5M	0.01%	1122
2024 Q2	$56.5M	Buy	+3,475,200	New	+$53.5M	0.01%	1081
2024 Q1	–	Sell	-2,305,500	Closed	-$24.1M	–	5878
2023 Q4	$24.1M	Sell	2,305,500 -759,900	-25%	-$7.09M	﹤0.01%	1734
2023 Q3	$31.3M	Hold	3,065,400	–	–	0.01%	1422
2023 Q2	$23.1M	Buy	3,065,400 +36,000	+1%	+$292K	﹤0.01%	1723
2023 Q1	$26.8M	Sell	3,029,400 -780,100	-20%	-$7.71M	0.01%	1557
2022 Q4	$34.7M	Hold	3,809,500	–	–	0.01%	1465
2022 Q3	$30.7M	Sell	3,809,500 -628,700	-14%	-$5.56M	0.01%	1498
2022 Q2	$33.4M	Buy	4,438,200 +478,900	+12%	+$4.17M	0.01%	1447
2022 Q1	$37.2M	Sell	3,959,300 -50,200	-1%	-$419K	0.01%	1551
2021 Q4	$32.1M	Buy	4,009,500 +3,871,700	+2,810%	+$34.9M	0.01%	1701
2021 Q3	$1.34M	Buy	+137,800	New	+$1.29M	﹤0.01%	4524
2021 Q1	–	Sell	-101,200	Closed	-$977K	–	6345
2020 Q4	$977K	Buy	101,200 +1,200	+1%	+$11.5K	﹤0.01%	4213
2020 Q3	$901K	Hold	100,000	–	–	﹤0.01%	4153
2020 Q2	$1.23M	Sell	100,000 -155,300	-61%	-$1.76M	﹤0.01%	3806
2020 Q1	$2.29M	Buy	+255,300	New	+$2.62M	﹤0.01%	3203
2019 Q2	–	Sell	-25,000	Closed	-$392K	–	5343
2019 Q1	$392K	Sell	25,000 -2,200	-8%	-$38.8K	﹤0.01%	4522
2018 Q4	$419K	Sell	27,200 -113,400	-81%	-$2.32M	﹤0.01%	4459
2018 Q3	$3.03M	Buy	140,600 +130,200	+1,252%	+$3.02M	﹤0.01%	3314
2018 Q2	$253K	Sell	10,400 -57,400	-85%	-$1.17M	﹤0.01%	4869
2018 Q1	$1.16M	Sell	67,800 -611,500	-90%	-$11.9M	﹤0.01%	3959
2017 Q4	$12.9M	Buy	679,300 +289,300	+74%	+$4.35M	﹤0.01%	2262
2017 Q3	$6.86M	Buy	390,000 +221,200	+131%	+$4.98M	﹤0.01%	2879
2017 Q2	$5.61M	Sell	168,800 -177,300	-51%	-$5.49M	﹤0.01%	2963
2017 Q1	$11.1M	Sell	346,100 -21,700	-6%	-$741K	﹤0.01%	2334
2016 Q4	$13.3M	Sell	367,800 -308,800	-46%	-$12.3M	﹤0.01%	2247
2016 Q3	$31.1M	Sell	676,600 -23,100	-3%	-$1.21M	0.01%	1569
2016 Q2	$35.1M	Sell	699,700 -328,800	-32%	-$17.5M	0.01%	1358
2016 Q1	$55M	Sell	1,028,500 -1,179,000	-53%	-$69.2M	0.02%	1020
2015 Q4	$145M	Buy	2,207,500 +2,054,800	+1,346%	+$127M	0.05%	479
2015 Q3	$8.62M	Buy	152,700 +66,000	+76%	+$4.28M	﹤0.01%	2372
2015 Q2	$5.12M	Sell	86,700 -221,200	-72%	-$13.6M	﹤0.01%	2935
2015 Q1	$19.2M	Sell	307,900 -309,800	-50%	-$18M	0.01%	1786
2014 Q4	$35.5M	Sell	617,700 -846,600	-58%	-$47.2M	0.01%	1377
2014 Q3	$78.7M	Sell	1,464,300 -889,600	-38%	-$47.1M	0.03%	770
2014 Q2	$123M	Sell	2,353,900 -1,017,100	-30%	-$52M	0.04%	563
2014 Q1	$178M	Buy	3,371,000 +851,000	+34%	+$39.3M	0.06%	361
2013 Q4	$101M	Buy	2,520,000 +2,029,500	+414%	+$79.9M	0.03%	632
2013 Q3	$18.5M	Sell	490,500 -317,100	-39%	-$12.4M	0.01%	1684
2013 Q2	$31.7M	Buy	+807,600	New	+$31.5M	0.01%	1199

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's TEVA Position: Q1 2026 in Review

Goldman Sachs reduced its Teva Pharmaceuticals (TEVA) stake by 18% in Q1 2026, selling an estimated $33.8M and leaving 4,826,245 shares worth $145M. The position accounts for 0.02% of the portfolio, ranked #835.

Goldman Sachs first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $328M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Goldman Sachs held 4,826,245 shares of Teva Pharmaceuticals worth $145M as of Q1 2026.
Goldman Sachs sold 1,051,822 Teva Pharmaceuticals shares in Q1 2026, an estimated $33.8M.
Teva Pharmaceuticals made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #835 holding.
Goldman Sachs first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Teva Pharmaceuticals position peaked at $328M in Q4 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.